Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase II research study that is designed for patients who have small cell lung cancer (SCLC) that is no longer responding to treatment. Patients will receive picoplatin, a new platinum-based agent that is currently under investigation, in 21-day cycles.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Poniard Pharmaceuticals

Criteria

Main inclusion criteria:

1. Diagnosis of small cell lung cancer.

2. Patients must have had one prior chemotherapy regimen which must have included either cisplatin or carboplatin.

[Additional eligibility criteria apply.]

Exclusion Criteria:

• Prior radiotherapy that included > 30% of the bone marrow (i.e., the whole of the pelvis or half of the spine).

• Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom.

• Significant heart disease.

• Uncontrolled, untreated, unstable, or symptomatic brain tumors or central nervous system disease.

• Grade 2+ peripheral neuropathy (a condition caused by damage to the nerves in the peripheral nervous system).

[Additional exclusion criteria apply.]